NASDAQ:NERV Minerva Neurosciences (NERV) Stock Price, News & Analysis $2.30 -0.08 (-3.36%) Closing price 04:00 PM EasternExtended Trading$2.31 +0.01 (+0.43%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Minerva Neurosciences Stock (NASDAQ:NERV) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Minerva Neurosciences alerts:Sign Up Key Stats Today's Range$2.26▼$2.4050-Day Range$2.20▼$4.6952-Week Range$1.96▼$8.80Volume74,463 shsAverage Volume205,172 shsMarket Capitalization$114.61 millionP/E RatioN/ADividend YieldN/APrice Target$10.33Consensus RatingHold Company Overview Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company based in Waltham, Massachusetts. It focuses on developing treatments for central nervous system disorders and does not have marketed products. The company’s principal drug candidate has been roluperidone, an oral medicine studied for negative symptoms of schizophrenia. The candidate remains investigational; its development has included clinical trials and regulatory review in the United States. Minerva’s earlier research pipeline has also included MIN-301, a biologic candidate studied for Parkinson’s disease. The company’s work is primarily focused on drug research and development rather than providing healthcare services directly.AI Generated. May Contain Errors. Read More Minerva Neurosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreNERV MarketRank™: 2.003010077215 of 5 starsMinerva Neurosciences scored higher than 40% of companies evaluated by MarketBeat, and ranked 685th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMinerva Neurosciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 1 sell rating.Upside PotentialMinerva Neurosciences has a consensus price target of $10.33, representing about 339.5% upside from its current price of $2.35.Amount of Analyst CoverageMinerva Neurosciences has only been the subject of 2 research reports in the past 90 days.Read more about Minerva Neurosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Minerva Neurosciences are expected to grow in the coming year, from ($0.73) to ($0.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Minerva Neurosciences is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Minerva Neurosciences is -0.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.04% of the float of Minerva Neurosciences has been sold short.Short Interest Ratio / Days to CoverMinerva Neurosciences has a short interest ratio ("days to cover") of 10.46, which indicates bearish sentiment.Change versus previous monthShort interest in Minerva Neurosciences has recently decreased by 21.20%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMinerva Neurosciences does not currently pay a dividend.Dividend GrowthMinerva Neurosciences does not have a long track record of dividend growth. News and Social Media1.0 / 5News Sentiment-0.40 News SentimentMinerva Neurosciences has a news sentiment score of -0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Minerva Neurosciences this week, compared to 2 articles on an average week. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Minerva Neurosciences insiders have not sold or bought any company stock.Percentage Held by Insiders1.70% of the stock of Minerva Neurosciences is held by insiders.Percentage Held by Institutions34.56% of the stock of Minerva Neurosciences is held by institutions.Read more about Minerva Neurosciences' insider trading history. Receive NERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NERV Stock News HeadlinesTranscript : Minerva Neurosciences, Inc. - Special CallNovember 13 at 2:57 AM | marketscreener.comMMinerva Neurosciences, Inc. (NERV) Discusses Roluperidone for Negative Symptoms of Schizophrenia TranscriptNovember 13 at 2:57 AM | seekingalpha.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 13 at 1:00 AM | Weiss Ratings (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: Humana (HUM), Minerva Neurosciences (NERV) and Moderna (MRNA)November 10 at 2:56 PM | theglobeandmail.comMinerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesNovember 6, 2026 | globenewswire.comMinerva Neurosciences, Inc (NERV) - What Are Investment Firms Thinking About This Stock?November 2, 2026 | americanbankingnews.comMinerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonOctober 29, 2026 | globenewswire.comMinerva Neurosciences to Host In-Person KOL Event to Discuss Roluperidone for Negative Symptoms of SchizophreniaOctober 28, 2026 | globenewswire.comSee More Headlines NERV Stock Analysis - Frequently Asked Questions How have NERV shares performed this year? Minerva Neurosciences' stock was trading at $4.02 on January 1st, 2026. Since then, NERV stock has decreased by 41.5% and is now trading at $2.3510. How were Minerva Neurosciences' earnings last quarter? Minerva Neurosciences, Inc (NASDAQ:NERV) released its quarterly earnings results on Friday, November, 6th. The biopharmaceutical company reported ($1.60) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by $1.46. When did Minerva Neurosciences' stock split? Minerva Neurosciences shares reverse split on the morning of Tuesday, June 21st 2022.The 1-8 reverse split was announced on Tuesday, June 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. When did Minerva Neurosciences IPO? Minerva Neurosciences (NERV) raised $33 million in an initial public offering (IPO) on Thursday, June 26th 2014. The company issued 5,454,545 shares at a price of $6.00 per share. Who are Minerva Neurosciences' major shareholders? Top institutional investors of Minerva Neurosciences include State Street Corp (1.22%). View institutional ownership trends. How do I buy shares of Minerva Neurosciences? Shares of NERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Minerva Neurosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Minerva Neurosciences investors own include NVIDIA (NVDA), Tesla (TSLA), NIO (NIO), Inovio Pharmaceuticals (INO), Moderna (MRNA), Alibaba Group (BABA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/06/2026Today11/13/2026Jefferies Global Healthcare Conference11/16/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 NERV's financial health is in the Red zone, according to TradeSmith. NERV has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NERV CIK1598646 Webwww.minervaneurosciences.com Phone(617) 600-7373FaxN/AEmployees7Year Founded2007Price Target and Rating Average Price Target for Minerva Neurosciences$10.33 High Price Target$14.00 Low Price Target$7.00 Potential Upside/Downside+347.7%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($28.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$293.42 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-28.95% Debt Debt-to-Equity RatioN/A Current Ratio33.02 Quick Ratio20.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.96) per share Price / Book-1.18Miscellaneous Outstanding Shares49,830,000Free Float48,988,000Market Cap$115.01 million OptionableOptionable Beta0.09 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:NERV) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredWhat Elon Musk's Cybercab Reveal Could Mean for InvestorsJeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredLast note from me on thisJoel Peterson's free workshop breaks down a three step, three color system that works across stocks, ETFs, gol...The Cycle Code | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Minerva Neurosciences, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Minerva Neurosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
